Upadacitinib

This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...

Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...

Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

This small case series suggests upadacitinib may induce and maintain steroid-free remission in some UC patients after tofacitinib failure, a potential option for people with refractory disease.

A new pediatric Phase 3 trial of filgotinib could broaden approved treatment choices for children and teens with moderate-to-severe ulcerative colitis, especially for those who have not responded to or cannot tolerate...

Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...

For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing...

People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...

Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...

Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...

A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...

If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...

A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...

People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.

For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...

This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...

Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.

This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help...

A new DailyMed label update for RINVOQ (upadacitinib) outlines FDA-approved uses that include Crohn’s disease and ulcerative colitis and highlights important safety warnings relevant to people with IBD. Patients and...

People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.

This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...

Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...

The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...

Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.

This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.

New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...

This study suggests acne is a common real-world side effect of upadacitinib for IBD and can affect treatment decisions and quality of life, especially for younger patients.

New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from msn.com.

This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.

This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.

Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Upadacitinib. Open the original article for the...

This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.

Based on the title and source metadata, this appears to be a clinical study related to Irritable bowel syndrome, Upadacitinib, and JAK inhibitor. The original article is from msn.com.

This study reports that upadacitinib produced clinical responses and steroid-free remission in a majority of patients with refractory Crohn's disease at 12 weeks, which may be relevant for people who have not responded...